2-Methyltryptamine CAS 2731-06-8 Purity >99.0% (HPLC) Panobinostat Intermediate Factory High Quality

Short Description:

Chemical Name: 2-Methyltryptamine

CAS: 2731-06-8

Purity: >99.0% (HPLC)

Appearance: Brown Solid

Intermediate of Panobinostat (CAS: 404950-80-7)

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Manufacturer Supply With High Quality, Commercial Production
Chemical Name: 2-Methyltryptamine CAS: 2731-06-8

Chemical Properties:

Chemical Name	2-Methyltryptamine
Synonyms	2-Methylindole-3-Ethylamine; 2-(2-Methyl-1H-indol-3-yl)ethanamine; 3-(2-Aminoethyl)-2-Methylindole
CAS Number	2731-06-8
CAT Number	RF-PI1480
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C11H14N2
Molecular Weight	174.25
Melting Point	106.0 to 110.0℃
Boiling Point	177℃/1.5mmHg(lit.)
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	Brown Solid
Purity / Analysis Method	>99.0% (HPLC Area)
1-HNMR	Consistent With Structure
Loss on Drying	<1.00%
Single Impurity	<0.50%
Total Impurities	<1.00%
Heavy Metals (as Pb)	<20ppm
Test Standard	Enterprise Standard
Usage	Pharmaceutical Intermediates; Panobinostat Intermediate

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

FAQ:

Application:

2-Methyltryptamine (CAS: 2731-06-8) is a key starting material in the synthesis of Panobinostat (LBH589) (CAS: 404950-80-7). Panobinostat is a potent inhibitor of all histone deacetylases (HDACs), with Ki values ranging from 0.6 to 31 nM for HDAC1-11. Through this action, it leads to acetylation of a range of cellular proteins, resulting in cell cycle arrest and apoptosis in cancer cells. Panobinostat is the first HDAC inhibitor was approved by FDA for the treatment of multiple myeloma. Panobinostat is marketed as Farydak, is used in combination with Bortezomib (CAS: 179324-69-7) and Dexamethasone (CAS: 50-02-2) to treat relapsed multiple myeloma after prior treatment with Bortezomib and an immunomodulator.